180 related articles for article (PubMed ID: 14265292)
21. COMPARATIVE PHARMACOLOGY OF ALKYLATING AGENTS. 3. TOXICITY DATA ON MONKEYS AND DOGS.
SCHMIDT LH; FRADKIN R; SULLIVAN R; FLOWERS A
Cancer Chemother Rep; 1965 Jan; 18():SUPPL 2:1017+. PubMed ID: 14278900
[No Abstract] [Full Text] [Related]
22. A STUDY OF COMPARATIVE CHEMICAL AND BIOLOGICAL ACTIVITIES OF ALKYLATING AGENTS.
BARDOS TJ; DATTA-GUPTA N; HEBBORN P; TRIGGLE DJ
J Med Chem; 1965 Mar; 8():167-74. PubMed ID: 14335145
[No Abstract] [Full Text] [Related]
23. THE INFLUENCE OF SOME SULFUR-CONTAINING COMPOUNDS ON THE TOXICITY OF NITROGEN MUSTARDS.
HIETBRINK BE; RAYMUND AB
Toxicol Appl Pharmacol; 1963 Nov; 5():735-49. PubMed ID: 14082479
[No Abstract] [Full Text] [Related]
24. POTENTIAL ANTICANCER AGENTS. II. THE SYNTHESIS OF SOME NITROGEN MUSTARD CONTAINING SULFONES AND THIOSULFINATES.
HIRSCH AF; PIANTADOSI C; IRVIN JL
J Med Chem; 1965 Jan; 8():10-4. PubMed ID: 14287239
[No Abstract] [Full Text] [Related]
25. Comparative antitumor effects of peptichemio and other alkylating agents.
Schmid FA; Banks SE; Stock CC
Cancer Treat Rep; 1977; 61(3):473-5. PubMed ID: 872145
[No Abstract] [Full Text] [Related]
26. A comparison between the hematological side effects of cyclophosphamide and nitrogen mustard.
NISSEN-MEYER R; HOST H
Cancer Chemother Rep; 1960 Nov; 9():51-5. PubMed ID: 13729268
[No Abstract] [Full Text] [Related]
27. SYSTEMIC THIOSULFATE PROTECTION DURING FRACTIONATED REGIONAL NITROGEN MUSTARD THERAPY.
LAWRENCE W; TAYAO MS; MAHAJAN RD; PAGE R; MILLER DG; CLAPP P
J Surg Res; 1964 Nov; 4():483-94. PubMed ID: 14224011
[No Abstract] [Full Text] [Related]
28. REDUCTION OF THE TOXICITY OF "RADIOMIMETIC" ALKYLATING AGENTS IN RATS BY THIOL PRETREATMENT. II. MECHANISM OF PROTECTION.
CALCUTT G; CONNORS TA; ELSON LA; ROSS WC
Biochem Pharmacol; 1963 Aug; 12():833-7. PubMed ID: 14071540
[No Abstract] [Full Text] [Related]
29. PROTECTION STUDIES WITH SODIUM THIOSULFATE AGAINST METHYL BIS (BETA-CHLOROETHYL)AMINE HYDROCHLORIDE (HN2) AND ITS ETHYLENIMONIUM DERIVATIVE.
BONADONNA G; KARNOFSKY DA
Clin Pharmacol Ther; 1965; 6():50-64. PubMed ID: 14253284
[No Abstract] [Full Text] [Related]
30. SOME OBSERVATIONS ON THE REACTIONS OF CHLORAMBUCIL, AZO-MUSTARD (CB 1414), AND CYCLOPHOSPHAMIDE.
ISRAELS LG; LINFORD JH
Proc Can Cancer Conf; 1963; 5():399-415. PubMed ID: 14278870
[No Abstract] [Full Text] [Related]
31. REDUCTION OF THE TOXICITY OF "RADIOMIMETIC" ALKYLATING AGENTS IN RATS BY THIOL PRE-TREATMENT. IV. PROTECTION AGAINST BONE MARROW DAMAGE.
CONNORS TA; DOUBLE JA; ELSON LA; JENEY A
Biochem Pharmacol; 1965 Apr; 14():569-77. PubMed ID: 14330623
[No Abstract] [Full Text] [Related]
32. [DEVELOPMENTAL DISORDER OF THE SKELETON CAUSED BY NITROGEN MUSTARD AND THE EFFECT OF VITAMIN E].
PLIESS G
Anat Anz; 1964 Aug; 115():119-22. PubMed ID: 14266943
[No Abstract] [Full Text] [Related]
33. THE EFFECTS OF ALKYLATING AGENTS ON FERTILITY.
JACKSON H
Br Med Bull; 1964 May; 20():107-14. PubMed ID: 14171898
[No Abstract] [Full Text] [Related]
34. [TEST OF THE ACTION OF SOME NITROGEN MUSTARD DERIVATIVES ON STICKER'S LYMPHOSARCOMA].
ZEZZANETO L; SOERENSEN B; SALIBA AM; GRECCHI R
Rev Bras Cir; 1963 Aug; 46():101-8. PubMed ID: 14097899
[No Abstract] [Full Text] [Related]
35. TOXICITY OF A NUCLEOTOXIC AGENT, MUSTINE HYDROCHLORIDE, AND ITS ENHANCEMENT BY 5-HYDROXYTRYPTAMINE PRETREATMENT.
UROIC B; RABADJIJA M; SUPEK Z
J Pharm Pharmacol; 1964 Jan; 16():61-2. PubMed ID: 14106568
[No Abstract] [Full Text] [Related]
36. [ON THE POSSIBILITY OF PROLONGING THE VIABILITY OF SKIN TRANSPLANTS IN RABBITS WITH ALKYLATING SUBSTANCES].
POPOV VI; NEZDATNYI MM
Patol Fiziol Eksp Ter; 1964; 8():37-9. PubMed ID: 14184390
[No Abstract] [Full Text] [Related]
37. STUDIES WITH MUSTARDS. V. IN VIVO FIXATION OF C14 OF LABELED ALKYLATING AGENTS BY BILATERALLY GROWN SENSITIVE AND RESISTANT TUMORS.
WHEELER GP; ALEXANDER JA
Cancer Res; 1964 Sep; 24():1331-7. PubMed ID: 14221791
[No Abstract] [Full Text] [Related]
38. Alkylating agents in bronchogenic carcinoma.
Green RA; Humphrey E; Close H; Patno ME
Am J Med; 1969 Apr; 46(4):516-25. PubMed ID: 5791000
[No Abstract] [Full Text] [Related]
39. [RESPONSE OF HEPATIC TISSUE OXIDOREDUCTION TO THE ADMINISTRATION OF NITROGEN MUSTARD IN THERAPEUTIC AND TOXIC DOSES].
CUTRONA E
Riv Patol Clin; 1963 Nov; 18():746-50. PubMed ID: 14125725
[No Abstract] [Full Text] [Related]
40. THE DURATION OF THE MYELOTOXIC EFFECTS OF CIRCULATING ALKYLATING AGENTS.
ULFOHN A; KRAMER SP; DORFMAN H; WITTEN B; WILLIAMSON C; SASS S; MILLER JI; SELIGMAN AM
Cancer Res; 1964 Oct; 24():1659-65. PubMed ID: 14234010
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
